File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Late term tolerance in head neck cancer patients irradiated in the IMRT era

TitleLate term tolerance in head neck cancer patients irradiated in the IMRT era
Authors
Issue Date2013
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.ro-journal.com
Citation
Radiation Oncology, 2013, v. 8, article no. 259 How to Cite?
AbstractBACKGROUND: The aim was to quantify severe transient and persisting late term effects in our single institution head neck cancer (HNC) cohort treated with curatively intended intensity modulated radiation therapy (IMRT). Hypothesis was if a 2-year follow up (FU) is sufficient to estimate the long term tolerance in HNC irradiated in the IMRT era. METHODS: Between 01/2002-8/2012, 707/1211 (58%) consecutively treated IMRT patients met the inclusion criteria of a FU time >12 months and loco-regional disease control (LRC). 45% presented with loco-regionally advanced disease; 55% were referred for curative definitive IMRT (66 Gy-72 Gy in 30-35 fractions), 45% underwent postoperative IMRT (60-66 Gy in 30-33 fractions). Systemic concomitant therapy was administered in 85%. Highly consistent treatment procedures were performed with respect to contouring processes, dose constraints, radiation schedules, and the use of systemic therapy. Grade 3/4 late term effects were prospectively assessed and analyzed with respect to subgroups at particular risk for specific late effects. RESULTS: Mean/median FU of the cohort was 41/35 months (15-124). 13% of the patients (92/707) experienced any grade 3/4 late effects (101 events in 92/707 patients), 81% in the first 12 months after radiation. 4% of all developed persisting late grade 3/4 effects (25 events in 25/707 patients). CONCLUSIONS: IMRT led to a high late term tolerance in loco-regionally disease free HNC patients. The onset of any G3/4 effects showed a plateau at 2 years. The question of the cervical vessel tolerance in disease free long time survivors is still open and currently under evaluation at our institution.
Persistent Identifierhttp://hdl.handle.net/10722/202458
ISSN
2015 Impact Factor: 2.466
2015 SCImago Journal Rankings: 1.278
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorStuder, Gen_US
dc.contributor.authorLinsenmeier, Cen_US
dc.contributor.authorRiesterer, Oen_US
dc.contributor.authorNajafi, Yen_US
dc.contributor.authorBrown, Men_US
dc.contributor.authorYousefi, Ben_US
dc.contributor.authorBredell, Men_US
dc.contributor.authorHuber, Gen_US
dc.contributor.authorSchmid, Sen_US
dc.contributor.authorStuder, Sen_US
dc.contributor.authorZwahlen, RAen_US
dc.contributor.authorRohrdorf, Ten_US
dc.contributor.authorGlanzmann, Cen_US
dc.date.accessioned2014-09-19T07:50:41Z-
dc.date.available2014-09-19T07:50:41Z-
dc.date.issued2013en_US
dc.identifier.citationRadiation Oncology, 2013, v. 8, article no. 259en_US
dc.identifier.issn1748-717X-
dc.identifier.urihttp://hdl.handle.net/10722/202458-
dc.description.abstractBACKGROUND: The aim was to quantify severe transient and persisting late term effects in our single institution head neck cancer (HNC) cohort treated with curatively intended intensity modulated radiation therapy (IMRT). Hypothesis was if a 2-year follow up (FU) is sufficient to estimate the long term tolerance in HNC irradiated in the IMRT era. METHODS: Between 01/2002-8/2012, 707/1211 (58%) consecutively treated IMRT patients met the inclusion criteria of a FU time >12 months and loco-regional disease control (LRC). 45% presented with loco-regionally advanced disease; 55% were referred for curative definitive IMRT (66 Gy-72 Gy in 30-35 fractions), 45% underwent postoperative IMRT (60-66 Gy in 30-33 fractions). Systemic concomitant therapy was administered in 85%. Highly consistent treatment procedures were performed with respect to contouring processes, dose constraints, radiation schedules, and the use of systemic therapy. Grade 3/4 late term effects were prospectively assessed and analyzed with respect to subgroups at particular risk for specific late effects. RESULTS: Mean/median FU of the cohort was 41/35 months (15-124). 13% of the patients (92/707) experienced any grade 3/4 late effects (101 events in 92/707 patients), 81% in the first 12 months after radiation. 4% of all developed persisting late grade 3/4 effects (25 events in 25/707 patients). CONCLUSIONS: IMRT led to a high late term tolerance in loco-regionally disease free HNC patients. The onset of any G3/4 effects showed a plateau at 2 years. The question of the cervical vessel tolerance in disease free long time survivors is still open and currently under evaluation at our institution.-
dc.languageengen_US
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.ro-journal.com-
dc.relation.ispartofRadiation Oncologyen_US
dc.rightsRadiation Oncology. Copyright © BioMed Central Ltd.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAntineoplastic Agents - administration and dosage-
dc.subject.meshHead and Neck Neoplasms - drug therapy - mortality - radiotherapy-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshRadiotherapy, Intensity-Modulated - methods-
dc.titleLate term tolerance in head neck cancer patients irradiated in the IMRT eraen_US
dc.typeArticleen_US
dc.identifier.emailZwahlen, RA: zwahlen@hku.hken_US
dc.identifier.authorityZwahlen, RA=rp00055en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/1748-717X-8-259-
dc.identifier.pmid24192223-
dc.identifier.hkuros237043en_US
dc.identifier.volume8en_US
dc.identifier.isiWOS:000327739100001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats